What is the appropriate management for a pediatric patient presenting with reactive airway disease (RDA) as an early or intermittent form of asthma?

Management of Pediatric Reactive Airway Disease

For children presenting with reactive airway disease (RAD)—an early or intermittent manifestation of asthma—you should diagnose and treat as asthma rather than using the RAD label, because RAD diagnoses delay preventive care by an average of 9 months without improving outcomes. 1

Why "Asthma" Instead of "RAD"

• Children diagnosed with RAD receive controller medications and asthma action plans only after a subsequent asthma diagnosis, typically 9 months after their initial presentation, despite having identical clinical outcomes to those initially labeled with asthma. 1
• The term "reactive airway disease" creates ambiguity that delays implementation of guideline-based preventive therapy without conferring any clinical benefit. 1
• Recurrent episodes of wheezing and cough triggered by viral upper respiratory infections, activity, or weather changes—especially when recovery takes longer than the typical week—indicate asthma in young children. 2

Initial Assessment of Severity

Identify children requiring immediate aggressive intervention by these features: 3

• Severe exacerbation markers: inability to speak or feed, respiratory rate >50 breaths/min, heart rate >140 beats/min, use of accessory muscles, or peak expiratory flow <50% predicted (in children ≥5 years). 3
• Life-threatening features: PEF <33% predicted, silent chest, cyanosis, poor respiratory effort, altered consciousness, or SpO₂ <92% despite supplemental oxygen. 3
• A normal or elevated PaCO₂ in a breathless child signals impending respiratory failure and mandates urgent escalation. 3

Acute Exacerbation Management (First Hour)

Bronchodilator Therapy

• Administer salbutamol 5 mg nebulized (or 2.5 mg for children ≤2 years or <15 kg) via oxygen-driven nebulizer every 20 minutes for three doses. 3
• Alternative delivery: metered-dose inhaler with large-volume spacer (4–8 puffs) every 20 minutes for three doses is equally effective and may reduce admission rates with fewer cardiovascular side effects. 3

Oxygen Support

• Provide high-flow oxygen via face mask to maintain SpO₂ >92% throughout treatment. 3

Systemic Corticosteroids

• Give prednisolone 1–2 mg/kg orally (maximum 40–60 mg) immediately upon recognition of acute symptoms. 3
• Continue for 3–5 days without taper if the course is <10 days. 3
• If the child is vomiting or critically ill, substitute IV hydrocortisone 100 mg every 6 hours (or 4 mg/kg per dose). 3

Ipratropium Bromide

• Add ipratropium 100–250 µg to each nebulizer treatment for moderate-to-severe attacks; repeat every 6 hours until improvement begins. 3

Reassessment at 15–30 Minutes

Measure PEF (if age ≥5 years), respiratory rate, heart rate, and SpO₂ after each bronchodilator dose. 3

Response-Guided Pathways

Good response (PEF >75% predicted, minimal symptoms): 3

• Continue usual maintenance therapy.
• Monitor with a PEF chart.
• Arrange follow-up within 48 hours.

Incomplete response (PEF 50–75% predicted, persistent symptoms): 3

• Maintain high-flow oxygen.
• Continue prednisolone.
• Give nebulized β-agonist every 4 hours.
• Consider hospital admission.

Poor response (PEF <50% predicted or ongoing severe features): 3

• Increase nebulized β-agonist to every 15–30 minutes.
• Continue ipratropium every 6 hours.
• Arrange immediate hospital admission.

Escalation for Refractory Cases

• If no improvement after the first reassessment, increase salbutamol frequency to every 15–30 minutes or switch to continuous nebulization. 3
• For life-threatening deterioration, give IV aminophylline 5 mg/kg over 20 minutes followed by maintenance infusion of 1 mg/kg/hour; omit the loading dose if the child is already on oral theophylline. 3
• Prepare for ICU transfer when indicated. 3

Long-Term Controller Therapy

When to Initiate Daily Controllers

If symptoms occur >2 days/week or >2 nights/month, the disease is classified as persistent asthma and requires daily controller therapy. 2

• Inhaled corticosteroids (ICS) are the preferred first-line daily controller for all age groups with persistent symptoms. 2
• Montelukast is approved for children ≥12 months and is often used for ease of daily oral dosing, though ICS remain preferred. 2
• Long-acting beta-2 agonists should only be used in combination with an ICS, never as monotherapy. 2

Trigger Avoidance

• Identify and avoid triggers through history: second-hand cigarette smoke, allergens confirmed by skin-prick testing, viral URIs, activity, and weather changes. 2
• Avoidance of identified triggers can significantly reduce symptom burden. 2

Hospital Admission Criteria

Admit immediately for: 3

• Any life-threatening feature.
• Persistent severe attack after initial therapy.
• PEF <50% after 1–2 hours of intensive treatment.
• Inability of caregivers to manage at home.
• Early deterioration after bronchodilators.
• Evening presentations, recent nocturnal symptoms, prior severe attacks, or poor social support (lower threshold for admission). 3

ICU Transfer Criteria

Transfer to intensive care for: 3

• Worsening PEF despite treatment.
• Increasing exhaustion or feeble respirations.
• Persistent/worsening hypoxia (SpO₂ <92%) or hypercapnia.
• Altered consciousness.
• Respiratory arrest or coma.

Discharge Planning

Discharge when: 3

• Stable on discharge medications for ≥24 hours with verified inhaler technique.
• PEF >75% predicted.
• Diurnal PEF variability <25%.
• Minimal or absent symptoms.

Prescribe at discharge: 3

• Prednisolone 1–2 mg/kg daily to complete a 3–5-day course.
• Inhaled corticosteroids alongside bronchodilators.
• Personal PEF meter with a written self-management plan.

Follow-up: 3

• GP visit within 1 week.
• Respiratory clinic review within 4 weeks.

Critical Pitfalls to Avoid

• Never delay systemic corticosteroids while giving repeated albuterol doses alone; this is a common cause of treatment failure and preventable mortality. 4
• Sedatives are absolutely contraindicated in acute pediatric asthma. 3
• Do not give an aminophylline bolus to children already receiving oral theophylline. 3
• Do not rely solely on subjective assessment; obtain objective measurements (PEF, SpO₂). 3
• Most children <7 years cannot use an unmodified MDI without a spacer device; always ensure proper technique and age-appropriate delivery. 4

Special Considerations for Preschool-Aged Children

• Approximately half of children with asthma present with symptoms before age 3 years. 2
• Wheezing is a common manifestation of viral respiratory infections in preschoolers, but recurrent episodes—especially those taking longer than a week to resolve—indicate asthma rather than transient viral wheezing. 2
• Early recognition and treatment with a trial of bronchodilator medication should show symptomatic improvement and confirm the diagnosis. 2
• The goal is to keep children "symptom free" by preventing chronic symptoms, maintaining lung function, and allowing normal daily activities. 2